The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma

G. Holló, D. Chiselita, N. Petkova, B. Cvenkel, I. Liehneova, B. Izgi, A. Berta, J. Szaflik, E. Turacli, William C. Stewart

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

PURPOSE. To compare the efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% when added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. DESIGN. A prospective, double-masked, randomized, active-controlled, parallel comparison. METHODS. Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily. Patients returned to clinic at Week 4 (Visit 3) for a safety visit and Week 12 (Visit 4) for an efficacy visit. At Visits 2 and 4 the intraocular pressure (IOP) was measured at 08:00, 12:00, and 16:00 hours. RESULTS. Ninety-seven patients on brinzolamide had a baseline diurnal IOP of 21.5±2.2 mmHg and 95 on timolol maleate had 21.3±2.5 mmHg, each added to travoprost. The diurnal mean IOP at Week 12 was 18.1±2.7 mmHg for brinzolamide and 18.1±3.0 mmHg for timolol maleate (p=0.96). There was no statistical difference found between treatment groups in the absolute level of pressure, or in the reduction in IOP from baseline, at each time point or for the diurnal curve (p>0.05). There was no significant difference for any adverse event between groups (p>0.05), with the most common side effect being conjunctival hyperemia in 15/97 (16%) brinzolamide and 6/95 (6%) timolol treated patients (p=0.06). CONCLUSIONS. This study showed that brinzolamide provides similar safety and efficacy compared to timolol maleate when added to travoprost.

Original languageEnglish
Pages (from-to)816-823
Number of pages8
JournalEuropean Journal of Ophthalmology
Volume16
Issue number6
Publication statusPublished - Nov 2006

Fingerprint

Timolol
Ocular Hypertension
Intraocular Pressure
Safety
Hyperemia
Travoprost
Primary Open Angle Glaucoma
brinzolamide
Pressure

Keywords

  • Brinzolamide
  • Ocular hypertension
  • Primary open-angle glaucoma
  • Timolol maleate
  • Travoprost

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. / Holló, G.; Chiselita, D.; Petkova, N.; Cvenkel, B.; Liehneova, I.; Izgi, B.; Berta, A.; Szaflik, J.; Turacli, E.; Stewart, William C.

In: European Journal of Ophthalmology, Vol. 16, No. 6, 11.2006, p. 816-823.

Research output: Contribution to journalArticle

Holló, G. ; Chiselita, D. ; Petkova, N. ; Cvenkel, B. ; Liehneova, I. ; Izgi, B. ; Berta, A. ; Szaflik, J. ; Turacli, E. ; Stewart, William C. / The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. In: European Journal of Ophthalmology. 2006 ; Vol. 16, No. 6. pp. 816-823.
@article{118b5e99903a45e8bc9ac281ab30e126,
title = "The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma",
abstract = "PURPOSE. To compare the efficacy and safety of timolol maleate 0.5{\%} versus brinzolamide 1{\%} when added to travoprost 0.004{\%} in patients with ocular hypertension or primary open-angle glaucoma. DESIGN. A prospective, double-masked, randomized, active-controlled, parallel comparison. METHODS. Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily. Patients returned to clinic at Week 4 (Visit 3) for a safety visit and Week 12 (Visit 4) for an efficacy visit. At Visits 2 and 4 the intraocular pressure (IOP) was measured at 08:00, 12:00, and 16:00 hours. RESULTS. Ninety-seven patients on brinzolamide had a baseline diurnal IOP of 21.5±2.2 mmHg and 95 on timolol maleate had 21.3±2.5 mmHg, each added to travoprost. The diurnal mean IOP at Week 12 was 18.1±2.7 mmHg for brinzolamide and 18.1±3.0 mmHg for timolol maleate (p=0.96). There was no statistical difference found between treatment groups in the absolute level of pressure, or in the reduction in IOP from baseline, at each time point or for the diurnal curve (p>0.05). There was no significant difference for any adverse event between groups (p>0.05), with the most common side effect being conjunctival hyperemia in 15/97 (16{\%}) brinzolamide and 6/95 (6{\%}) timolol treated patients (p=0.06). CONCLUSIONS. This study showed that brinzolamide provides similar safety and efficacy compared to timolol maleate when added to travoprost.",
keywords = "Brinzolamide, Ocular hypertension, Primary open-angle glaucoma, Timolol maleate, Travoprost",
author = "G. Holl{\'o} and D. Chiselita and N. Petkova and B. Cvenkel and I. Liehneova and B. Izgi and A. Berta and J. Szaflik and E. Turacli and Stewart, {William C.}",
year = "2006",
month = "11",
language = "English",
volume = "16",
pages = "816--823",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "6",

}

TY - JOUR

T1 - The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma

AU - Holló, G.

AU - Chiselita, D.

AU - Petkova, N.

AU - Cvenkel, B.

AU - Liehneova, I.

AU - Izgi, B.

AU - Berta, A.

AU - Szaflik, J.

AU - Turacli, E.

AU - Stewart, William C.

PY - 2006/11

Y1 - 2006/11

N2 - PURPOSE. To compare the efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% when added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. DESIGN. A prospective, double-masked, randomized, active-controlled, parallel comparison. METHODS. Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily. Patients returned to clinic at Week 4 (Visit 3) for a safety visit and Week 12 (Visit 4) for an efficacy visit. At Visits 2 and 4 the intraocular pressure (IOP) was measured at 08:00, 12:00, and 16:00 hours. RESULTS. Ninety-seven patients on brinzolamide had a baseline diurnal IOP of 21.5±2.2 mmHg and 95 on timolol maleate had 21.3±2.5 mmHg, each added to travoprost. The diurnal mean IOP at Week 12 was 18.1±2.7 mmHg for brinzolamide and 18.1±3.0 mmHg for timolol maleate (p=0.96). There was no statistical difference found between treatment groups in the absolute level of pressure, or in the reduction in IOP from baseline, at each time point or for the diurnal curve (p>0.05). There was no significant difference for any adverse event between groups (p>0.05), with the most common side effect being conjunctival hyperemia in 15/97 (16%) brinzolamide and 6/95 (6%) timolol treated patients (p=0.06). CONCLUSIONS. This study showed that brinzolamide provides similar safety and efficacy compared to timolol maleate when added to travoprost.

AB - PURPOSE. To compare the efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% when added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. DESIGN. A prospective, double-masked, randomized, active-controlled, parallel comparison. METHODS. Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily. Patients returned to clinic at Week 4 (Visit 3) for a safety visit and Week 12 (Visit 4) for an efficacy visit. At Visits 2 and 4 the intraocular pressure (IOP) was measured at 08:00, 12:00, and 16:00 hours. RESULTS. Ninety-seven patients on brinzolamide had a baseline diurnal IOP of 21.5±2.2 mmHg and 95 on timolol maleate had 21.3±2.5 mmHg, each added to travoprost. The diurnal mean IOP at Week 12 was 18.1±2.7 mmHg for brinzolamide and 18.1±3.0 mmHg for timolol maleate (p=0.96). There was no statistical difference found between treatment groups in the absolute level of pressure, or in the reduction in IOP from baseline, at each time point or for the diurnal curve (p>0.05). There was no significant difference for any adverse event between groups (p>0.05), with the most common side effect being conjunctival hyperemia in 15/97 (16%) brinzolamide and 6/95 (6%) timolol treated patients (p=0.06). CONCLUSIONS. This study showed that brinzolamide provides similar safety and efficacy compared to timolol maleate when added to travoprost.

KW - Brinzolamide

KW - Ocular hypertension

KW - Primary open-angle glaucoma

KW - Timolol maleate

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=33846500434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846500434&partnerID=8YFLogxK

M3 - Article

C2 - 17191187

AN - SCOPUS:33846500434

VL - 16

SP - 816

EP - 823

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 6

ER -